Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials | JOURNAL FOR IMMUNOTHERAPY OF CANCER |